PMID- 15190381
OWN - NLM
STAT- MEDLINE
DCOM- 20040629
LR  - 20181130
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 40 Suppl A
DP  - 2004 Mar
TI  - GERD 2003: issues from the past and a consensus for the future.
PG  - 3-8
AB  - Gastroesophageal reflux disease (GERD) has evolved from a scarcely reported, 
      little understood disease process just a century ago to a now highly prevalent 
      disease with up to 25% of the population complaining of symptoms of reflux. 
      Throughout history attempts have been made to delineate the esophagus and related 
      pathologies, but it has not been until relatively recently that enough has been 
      understood about its screening, diagnosis and treatment to make a substantial 
      impact on sufferers. Although the use of antacids and thereafter histamine 2 
      receptor antagonists dramatically improved the management of GERD, it was the 
      advent of the proton pump inhibitor (PPI) class of drugs that revolutionized 
      medical care. Although the relationship of hiatus hernia to reflux was well 
      accepted, the modest results of open fundoplication fell into further disregard 
      given the efficacy of PPIs. The PPIs are currently the most effective form of 
      therapy and are equivalent on a milligram for milligram basis. While currently no 
      novel drugs or devices are of proven efficacy for GERD, the development of an 
      acid-suppressive agent of equal efficiency to a PPI but with a more rapid onset 
      of action and a greater duration of effectiveness would be of particular clinical 
      utility for the future.
CI  - (c) 2004 Prous Science
FAU - Modlin, Irvin
AU  - Modlin I
AD  - Gastric Pathology Research Group, Department of Surgery, Yale University, School 
      of Medicine, New Haven, CT 06520-8062, USA.
FAU - Kidd, Mark
AU  - Kidd M
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Sulfoxides)
RN  - D8TST4O562 (Pantoprazole)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Anti-Ulcer Agents/*history/therapeutic use
MH  - Benzimidazoles/*history/therapeutic use
MH  - Esophagitis, Peptic/history/therapy
MH  - Gastroesophageal Reflux/*history/therapy
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Omeprazole/*history/therapeutic use
MH  - Pantoprazole
MH  - Postoperative Complications
MH  - Proton Pump Inhibitors
MH  - Sulfoxides/*history/therapeutic use
EDAT- 2004/06/11 05:00
MHDA- 2004/06/30 05:00
CRDT- 2004/06/11 05:00
PHST- 2004/06/11 05:00 [pubmed]
PHST- 2004/06/30 05:00 [medline]
PHST- 2004/06/11 05:00 [entrez]
AID - 2458 [pii]
PST - ppublish
SO  - Drugs Today (Barc). 2004 Mar;40 Suppl A:3-8.